← Markets

Kailera Therapeutics, Inc.

KLRA · NASDAQ

Market closed$18.55$0.230000 (+1.26%)After hours $18.00 · -2.97%

Key statistics

Previous close$18.32
Open$17.90
Day high$18.87
Day low$17.61
52-week high$28.23
52-week low$17.61
Market cap2.40B
Volume341.39K
Average volume796.30K
P/E ratio-0.01
Forward P/E—
EPS-3.65K
Dividend yield0.00%

Market context

Why it moved

KLRA edged higher as investors recalibrated positions following recent pressure on the stock tied to lackluster weight-loss pill trial results, with modest buying interest suggesting a partial recovery from its recent decline.

OedigitalMarketbeatErrAdhoFacebook

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Kailera Therapeutics edged higher on Thursday despite near-term headwinds, including a 96% surge in short interest in June to over 5 million shares, and shares recently touching a new 52-week low near $18.39. Wall Street remains broadly bullish with a consensus 'Buy' rating and an average price target of $42.75 — well above current levels — with coverage from JPMorgan, Jefferies, William Blair, and TD Cowen, while insider buying remains a key signal of confidence, with directors purchasing over 9.9 million shares worth ~$167 million in the past 90 days. In after-hours trading, KLRA slipped ~3% as broader market sentiment soured on AI concerns, escalating U.S.-Iran tensions, and a weak Netflix forecast weighing on risk appetite.

1.2555

July 17, 2026Kailera Therapeutics tumbled to a new 52-week low of $17.98, closing down over 5%, as a sharp rise in short interest — up 96% in June — weighed on sentiment for the clinical-stage obesity biotech. Despite the pressure, Wall Street remains constructive with an average analyst price target of $42.75 and a consensus Buy rating, while insiders have aggressively accumulated shares, purchasing over 10.4 million shares worth ~$167 million in the past 90 days. The GLP-1 space broadly remains competitive and closely watched, with Novo Nordisk's continued momentum underscoring the sector's appeal.

-5.0777

July 15, 2026Kailera Therapeutics edged higher, buoyed by growing investor interest in the GLP-1 obesity drug space after a new Gallup survey showed record numbers of Americans taking weight-loss medications. The clinical-stage biotech, whose lead candidate ribupatide is in global Phase 3 trials as a GLP-1/GIP dual agonist, carries a consensus Buy rating and an average analyst price target of $42.75 — more than double its current price — though the stock remains well off its post-IPO highs amid a recent pullback following oral GLP-1 trial data in early July. Analyst commentary highlighting Kailera as a 'beaten-down' GLP-1 buying opportunity, alongside UBS upgrading the broader healthcare and biotech sector as an M&A rebound candidate, supported sentiment.

1.5255

July 14, 2026Kailera Therapeutics fell sharply, declining nearly 5% on a day when biotech broadly faced headwinds—FactSet projects sector earnings to drop 79% year-over-year in Q2, the steepest decline across all healthcare industries. The selloff came amid a volatile macro backdrop, with Iran-U.S. tensions reigniting, oil surging, and investors rotating out of higher-risk, pre-revenue names; the healthcare sector ETF (XLV) also softened as major constituents like J&J, UnitedHealth, and Abbott head into earnings this week.

-4.8072

July 11, 2026Kailera Therapeutics declined modestly, giving back some gains following the July 7 announcement of positive Phase 3 topline data for its oral GLP-1 agonist KAI-7535, which showed up to 11.1% mean weight loss and met primary endpoints in both obesity and type 2 diabetes trials in China. Despite the encouraging data, the initial market reaction was negative — shares fell ~4.55% on the day of the announcement — as investors weighed the China-only trial context and the global Phase 2 readout not expected until 2027. Jefferies maintained its Buy rating and $48 price target, and analyst consensus remains bullish with a $42.75 target implying ~96% upside, while biotech broadly continued to outperform as Jim Cramer called the sector the market's hottest group.

-1.5707

July 10, 2026Kailera Therapeutics fell nearly 3.5% Thursday, continuing to digest the market's muted reaction to its July 7 announcement of positive Phase 3 topline data for oral GLP-1 agonist KAI-7535, which showed up to 11.1% mean weight loss but initially triggered a selloff on concerns about how its profile compares to leading injectables. The decline comes despite a broadly favorable environment for biotech — healthcare has been the S&P 500's top-performing sector for two consecutive weeks, and Jim Cramer recently called biotech "the hottest group in the market" amid a wave of M&A activity — suggesting investor hesitation around KAI-7535's competitive positioning in the crowded oral GLP-1 space ahead of global Phase 2 data expected in 2027.

-3.4467

July 8, 2026Kailera Therapeutics fell sharply after reporting positive topline Phase 3 data for its oral GLP-1 drug KAI-7535, as investors focused on elevated gastrointestinal side effects rather than the efficacy wins. Both the HARBOR-1 (obesity) and OUTSTAND-2 (type 2 diabetes) trials met their primary endpoints — with up to 11.1% mean weight loss at Week 50 — but nausea and vomiting affected ~70% and ~67% of patients, respectively, raising competitiveness concerns. TD Cowen maintained a Buy rating with a $57 price target, while William Blair noted that reducing GI side effect rates in the ongoing global Phase 2 trial (data expected 2027) will be key to a competitive profile. Shares recovered modestly in after-hours trading, up ~2%.

-4.5494

July 6, 2026Kailera Therapeutics surged nearly 6% as reports emerged that Pfizer is exploring an acquisition of the company to bolster its weight loss drug portfolio. The potential deal, which would give Pfizer a foothold in the competitive obesity and metabolic disease space, sparked strong investor enthusiasm for KLRA even as the broader healthcare sector faced headwinds. Shares are holding their gains in after-hours trading, essentially unchanged from the regular session close.

5.9573

pharmaphorum · July 10, 2026Kailera's big obesity reveal puts pressure on sharesMoomoo · July 8, 2026TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $57Reuters · July 7, 2026Kailera shares tumble on high nausea rates despite weight-loss drug's successStock Titan · July 7, 2026Kailera's oral GLP-1 pill posted 11.1% weight loss in Phase 3BioPharma Dive · July 7, 2026Kailera says obesity pill succeeds in late-stage trial in ChinaBioSpace · June 8, 2026ADA: Kailera ‘back at work’ after record-breaking IPO with China data in handInvestor's Business Daily · May 12, 2026Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In ObesityTradingView · April 23, 2026Bain Capital Life Sciences Secures Board Role at Kailera Therapeutics with 17.4% Stake
Mt Newswire · July 7, 2026Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall
Benzinga · July 7, 2026Why Is Kailera Therapeutics Stock Falling Tuesday?
Mt Newswire · July 7, 2026Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial
Benzinga · July 7, 2026Kailera Therapeutics Announces Topline Data From Two Additional Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535 Conducted By Hengrui Pharma In China
Benzinga · May 26, 2026Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M
Benzinga · May 13, 2026This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
Benzinga · May 13, 2026Hengrui Pharma, Kailera Therapeutics To Present Two Abstracts At 86th Scientific Sessions Of The American Diabetes Association
Benzinga · May 12, 2026Leerink Partners Initiates Coverage On Kailera Therapeutics with Outperform Rating, Announces Price Target of $36

Peers

S&P 500SPX · $7,457.69-1.01%Viking Therapeutics, Inc.VKTX · $37.08+1.95%Structure Therapeutics Inc.GPCR · $48.48+5.32%Krystal Biotech, Inc.KRYS · $354.86+3.82%Cytokinetics, IncorporatedCYTK · $80.18-0.22%ImmunityBio, Inc.IBRX · $7.68+3.09%Nuvalent, Inc.NUVL · $123.960.00%Novo Nordisk A/SNVO · $50.32-2.25%Eli Lilly and CompanyLLY · $1,179.09+0.85%Arcus Biosciences, Inc.RCUS · $27.37+2.74%Vertex Pharmaceuticals IncorporatedVRTX · $485.65-0.08%Regeneron Pharmaceuticals, Inc.REGN · $676.69-0.33%